Sight Sciences (NASDAQ:SGHT - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Sight Sciences to post earnings of ($0.25) per share and revenue of $18.18 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. The firm had revenue of $17.51 million during the quarter, compared to analysts' expectations of $16.51 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Sight Sciences Stock Down 1.8%
Sight Sciences stock traded down $0.06 during trading on Friday, reaching $3.27. 229,807 shares of the company's stock were exchanged, compared to its average volume of 207,237. The company's 50-day moving average is $3.83 and its two-hundred day moving average is $3.14. The company has a debt-to-equity ratio of 0.51, a quick ratio of 9.99 and a current ratio of 10.47. Sight Sciences has a 52-week low of $2.03 and a 52-week high of $7.12. The firm has a market cap of $169.05 million, a price-to-earnings ratio of -3.34 and a beta of 2.47.
Insider Activity at Sight Sciences
In other news, insider Jeremy B. Hayden sold 9,160 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total value of $38,197.20. Following the completion of the transaction, the insider directly owned 266,321 shares in the company, valued at $1,110,558.57. This trade represents a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Paul Badawi sold 23,637 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $4.15, for a total transaction of $98,093.55. Following the sale, the chief executive officer owned 5,986,943 shares of the company's stock, valued at $24,845,813.45. The trade was a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,365 shares of company stock valued at $180,017 over the last quarter. Insiders own 30.90% of the company's stock.
Institutional Investors Weigh In On Sight Sciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in Sight Sciences in the 1st quarter worth $158,000. AQR Capital Management LLC acquired a new stake in shares of Sight Sciences during the 1st quarter valued at about $128,000. Finally, Rhumbline Advisers lifted its holdings in Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company's stock valued at $120,000 after purchasing an additional 4,319 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have commented on SGHT. Wall Street Zen lowered shares of Sight Sciences from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Citigroup reaffirmed a "neutral" rating and set a $3.60 price target (up previously from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Lake Street Capital increased their price target on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research report on Friday, May 9th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up previously from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Sight Sciences has a consensus rating of "Hold" and a consensus target price of $3.93.
Get Our Latest Report on SGHT
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
